THE WIRE · № 82180
Moderna, Google DeepMind, Biocon on AI in Science
01 THE MACHINE READ
WHY IT MATTERS.
Executives from Moderna, DeepMind and Biocon discussing AI in science supports the long-run drug-discovery productivity narrative.
AI drug-discovery narrative reinforced by executives
Trial results from AI-designed drugs
Long timelines, uncertain commercial payoff
FULL DISPATCH
Noubar Afeyan, Co-Founder & Chairman, Moderna and Founder & CEO, Flagship Pioneering; Lila Ibrahim, Chief AI Readiness Officer, Google DeepMind; and Kiran Mazumdar-Shaw, Founder & Executive Chairperson, Biocon discuss how AI is reshaping scientific discovery with Bloomberg's Francine Lacqua at the 2
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
Innover Digital Named an OpenAI Select Partner to Help Enterprises Put Agentic AI to Work in Core Operations2026-10-15 13:30 UTC
Greenhouse Launches the Orchestrated Hiring Ecosystem to Break AI's Hiring Doom Loop2026-10-15 13:30 UTC
UWorld Adds Automated Proctoring to Its Nursing Learning Platform to Ease Faculty Workload2026-10-15 13:35 UTC
VIO Med Spa Expands West with Arizona Debut in Queen Creek and Scottsdale2026-10-15 13:36 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.